Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is approved in the US, EU, and other regions for the treatment of adults with type 2 diabetes mellitus (T2DM). This review summarizes the ertugliflozin pharmacokinetic (PK) and pharmacodynamic data obtained during phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Fediuk, Daryl J., Nucci, Gianluca, Dawra, Vikas Kumar, Cutler, David L., Amin, Neeta B., Terra, Steven G., Boyd, Rebecca A., Krishna, Rajesh, Sahasrabudhe, Vaishali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403171/
https://www.ncbi.nlm.nih.gov/pubmed/32337660
http://dx.doi.org/10.1007/s40262-020-00875-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403171/
https://www.ncbi.nlm.nih.gov/pubmed/32337660
http://dx.doi.org/10.1007/s40262-020-00875-1

Ejemplares similares